CHOW SANG SANG (00116) third quarter retail sales value increased by 3% year-on-year.
Chow Sang Sang (00116) announced that the Group's retail sales value grew by 3% in the current quarter (the three months ended September 30, 2026), with positive same-store sales growth recorded in Mainland China, Hong Kong and Macau, China, and Taiwan, China.
CHOW SANG SANG (00116) announced that the Group's retail sales value grew by 3% in the current quarter (the three months ended September 30, 2026), with same-store sales growth in Mainland China, Hong Kong and Macau, and Taiwan all recording positive growth.
Demand for gold jewellery remained resilient in the current quarter, with priced gold jewellery continuing to be favoured by the market in Mainland China. Customer demand in Hong Kong and Macau was broad-based, continuing to drive sales growth.
In the current quarter, the Group further expanded its retail network layout across various markets by upgrading certain branches in prime locations, opening a third branch at The Venetian Macao, and opening its first "Chow Sang Sang" boutique in Taipei.
Related Articles
HK Stock Market Move | ALEBUND-B(09637) rose nearly 4% at one point during intraday trading, with an amplitude of 13.53%. Hong Kong-listed innovative drug stocks strengthened collectively. AP308, a new drug for the treatment of IgA nephropathy, received approval from the U.S. FDA for clinical trials.
BUTONG GROUP (06090) repurchased 110,000 shares for HK$3.8656 million on October 15.
LEADS BIOLABS-B(09887): First Patient Dosed in Phase IB/II Clinical Trial of Vilixin (Opatilimab, PD-L1/41BB Bispecific Antibody) in Combination Therapy for Metastatic Colorectal Cancer
HK Stock Market Move | ALEBUND-B(09637) rose nearly 4% at one point during intraday trading, with an amplitude of 13.53%. Hong Kong-listed innovative drug stocks strengthened collectively. AP308, a new drug for the treatment of IgA nephropathy, received approval from the U.S. FDA for clinical trials.
BUTONG GROUP (06090) repurchased 110,000 shares for HK$3.8656 million on October 15.
LEADS BIOLABS-B(09887): First Patient Dosed in Phase IB/II Clinical Trial of Vilixin (Opatilimab, PD-L1/41BB Bispecific Antibody) in Combination Therapy for Metastatic Colorectal Cancer
